13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q3 2024 · Filed November 14, 2024 · Accession 0001012975-24-000476
Total Value
$260.6M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BEAM THERAPEUTICS INC. | BEAM | 4,834,653 | $118.4M | 45.46% |
| 2 | RAPPORT THERAPEUTICS, INC. | RAPP | 3,728,738 | $76.4M | 29.31% |
| 3 | ERASCA, INC. | ERAS | 11,055,554 | $30.2M | 11.58% |
| 4 | Q32 BIO INC. | QTTB | 320,482 | $14.3M | 5.49% |
| 5 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $9.7M | 3.73% |
| 6 | GOSSAMER BIO, INC. | GOSS | 8,055,916 | $7.9M | 3.05% |
| 7 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R308 | 126,630 | $2.0M | 0.76% |
| 8 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $1.5M | 0.57% |
| 9 | CERO THERAPEUTICS HOLDINGS, INC. | 71902K105 | 1,444,296 | $134,753 | 0.05% |